CN103833553A - Midbody for preparing agomelatine and preparation method thereof - Google Patents

Midbody for preparing agomelatine and preparation method thereof Download PDF

Info

Publication number
CN103833553A
CN103833553A CN201410060403.5A CN201410060403A CN103833553A CN 103833553 A CN103833553 A CN 103833553A CN 201410060403 A CN201410060403 A CN 201410060403A CN 103833553 A CN103833553 A CN 103833553A
Authority
CN
China
Prior art keywords
formula
preparation
compound
reaction
agomelatine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201410060403.5A
Other languages
Chinese (zh)
Other versions
CN103833553B (en
Inventor
张现毅
俞建斌
高红军
车大庆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Jiuzhou Pharmaceutical Co Ltd
Original Assignee
Zhejiang Jiuzhou Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Jiuzhou Pharmaceutical Co Ltd filed Critical Zhejiang Jiuzhou Pharmaceutical Co Ltd
Priority to CN201410060403.5A priority Critical patent/CN103833553B/en
Publication of CN103833553A publication Critical patent/CN103833553A/en
Application granted granted Critical
Publication of CN103833553B publication Critical patent/CN103833553B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/62—Halogen-containing esters
    • C07C69/63—Halogen-containing esters of saturated acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/02—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C247/00—Compounds containing azido groups
    • C07C247/02—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C247/08—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being unsaturated
    • C07C247/10—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being unsaturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01—Preparation of ethers
    • C07C41/16—Preparation of ethers by reaction of esters of mineral or organic acids with hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01—Preparation of ethers
    • C07C41/18—Preparation of ethers by reactions not forming ether-oxygen bonds
    • C07C41/30—Preparation of ethers by reactions not forming ether-oxygen bonds by increasing the number of carbon atoms, e.g. by oligomerisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/08—Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention relates to the technical field of a preparation method of carboxylic acid amide, and particularly relates to the technical field of agomelatine and a preparation method of an agomelatine midbody. The invention particularly discloses the agomelatine midbody and a preparation method thereof. The preparation method of the midbody comprises the steps that 1-halogen-7-alkoxy naphthalene is used as a raw material and is subjected to alkylation reaction so as to obtain a compound shown in a formula (2), the obtained compound shown in the formula (2) is subjected to grignard reaction so as to obtain a compound shown in a formula (3), the compound shown in the formula (3) reacts with trifluoroacetic anhydride so as to obtain a compound shown in a formula (4), and the compound shown in the formula (4) is a new midbody compound for synthesizing agomelatine and derivatives thereof; meanwhile the compound shown in the formula (4) reacts with sodium azide so as to obtain a compound shown in a formula (5), which is also a new midbody compound for synthesizing agomelatine and derivatives thereof; and the agomelatine and agomelatine derivatives suitable for industrial production can be obtained through simple reaction such as hydrogenation reaction, electrophilic substitution and the like of the compound shown in the formula (5), wherein in the formula, R is an alkyl radical, and X is F, Cl, Br and I.

Description

For the preparation of intermediate and the related manufacturing processes of Agomelatine
The application is to be on December 21st, 2010 applying date, and application number is CN201010615618.0, and denomination of invention is the divisional application of the patent application of " for the preparation of intermediate and the related manufacturing processes of Agomelatine ".
Technical field
The present invention relates to preparation method's technical field of carboxylic acid amide, relate in particular to Agomelatine and intermediate preparation method technical field thereof.
Background technology
Melatonin receptor agonist thymoleptic Agomelatine has obtained listing approval on February 19th, 2009 in European Union, and its commodity are by name
Figure BDA0000468230020000011
agomelatine (Agomelatine), chemistry is by name: N-[2-(7-methoxy-1-naphthyl) ethyl] ethanamide is a kind of melatonin by the research and development of French Shi Weiya company 1,2(MT 1mT 2) agonist of acceptor, be also the antagonist of serotonin 2c (5HT2c) acceptor simultaneously, be mainly used in clinically treatment adult dysthymia disorders.
Figure BDA0000468230020000012
About Agomelatine preparation, carry out a lot of research work at present.In existing synthetic route, every route has one's own knack, and also all has certain shortcoming simultaneously.Common synthetic route mainly contains following several both at home and abroad at present.Route one: French Shi Weiya company disclosed synthetic route in the granted patent EP447285 of Europe acquisition is as follows:
Figure BDA0000468230020000013
This route shortcoming is for 1. when the preparation formula VIII compound, and using the larger allyl methacrylate(AMA) of toxicity is dehydrogenating agent, and temperature of reaction is up to more than 200 ℃, and operation easier is larger.Can obtain endo isomer compound formula III by formula II compound through Reformatsky reaction generation formula III compound '.
Figure BDA0000468230020000014
The mixture obtaining thus, and endo isomer compound formula III ' needing violent aromizing, its subsequent step is incomplete often; 2. high by formula VIII compounds accepted way of doing sth IX hydrogenation of compounds pressure, in patent, report that pressure is 300atm; 3. reactions steps is long, and average yield is less than 30%.
Route two: it is as follows that French Servier Lab announces route at Chinese granted patent CN101041629:
Figure BDA0000468230020000021
This route shortcoming is in the time of preparation formula VIII compound, and using the larger allyl methacrylate(AMA) of toxicity is dehydrogenating agent, and temperature of reaction is up to more than 200oC, and operation easier is larger.
Route three: it is as follows that the patent application CN101792400 of East China Normal University announces route:
Figure BDA0000468230020000022
This route shortcoming is 1. to use inflammable n-Butyl Lithium when preparation formula B compound, and needs to use the very low temperature of-70 ℃, and operation easier is larger; 2. need to use when preparation formula VIII compound expensive DDQ (DDQ) as de-agent, and DDQ environmental pollution is larger, is unfavorable for environment protection; 3. use inflammable Lithium Aluminium Hydride as reductive agent when preparation formula IX compound, be unfavorable for industrialization.
Route four: it is as follows that French Servier Lab announces route at the patent CN101643434 of China's application subsequently:
Figure BDA0000468230020000023
This route shortcoming during for 1. synthesis type b compound, is used expensive trifluoromethanesulfanhydride anhydride, and production cost is larger; 2. in preparation formula c compound process, use expensive tetra-triphenylphosphine palladium, be unfavorable for industrialization.
In view of the good medicinal application prospect of Agomelatine, need to develop that a kind of raw material is cheap and easy to get, processing safety is high, reaction reagent cost is low, be easy to industrialized operational path.
Summary of the invention
The object of the invention is to overcome in above-mentioned prior art starting raw material expensive, be difficult for realizing the shortcomings such as industrialization, two kinds of new midbody compounds for the preparation of Agomelatine and related manufacturing processes are provided.
To achieve these goals, one of the technical solution used in the present invention is: a kind of midbody compound for the preparation of Agomelatine is provided, and its structural formula is as follows:
Figure BDA0000468230020000031
Wherein: R 1for alkyl.
Described alkyl is preferably C 1～C 20straight or branched alkyl, more preferably C 1～C 8straight or branched alkyl.
Described alkyl specifically can be methyl, ethyl, propyl group, sec.-propyl, normal-butyl, the tertiary butyl, isobutyl-.
Two of the technical solution used in the present invention is: a kind of method with preparation formula 6 compounds is provided, has comprised the steps:
Following formula 5 compounds obtain formula 6 compounds of following formula through hydro-reduction.
Figure BDA0000468230020000032
Wherein R 1identical with above-mentioned definition.
Described hydro-reduction used catalyst is preferably palladium carbon, metal platinum, the oxide compound of metal platinum or Raney's nickel, more preferably palladium carbon.
The quality amount ratio of described formula 5 compounds and described hydro-reduction catalyzer is preferably 1:(0.01～0.1) 1:(0.1～0.5 more preferably).
Described reaction solvent for use is preferably alcohols or ethers, or its any mixture.Described alcoholic solvent is preferably methyl alcohol, ethanol, and Virahol, n-propyl alcohol, propyl carbinol or its be two or more mixture arbitrarily.Described ether solvent is preferably tetrahydrofuran (THF), methyltetrahydrofuran.Solvent for use consumption is 20～80 times of formula 5 compounds, preferably 30～50 times.
The temperature of reaction of described reaction is 0～200 ℃, is preferably 25～100 ℃.Reaction times is 0.5～48 hour, is preferably 5～12 hours.
Preferably 0.1～10Mpa of hydrogen pressure used in reaction process; More preferably 1.0～1.5Mpa.
Three of the technical solution used in the present invention is: the another kind of midbody compound for the preparation of Agomelatine is provided, and its structural formula is as follows:
Figure BDA0000468230020000033
Wherein R 1identical with above-mentioned definition.
Four of the technical solution used in the present invention is: a kind of method for the preparation of following formula 5 compounds is provided, has comprised the steps:
Following formula 4 compounds, under sodiumazide effect, generate following formula 5 compounds,
Figure BDA0000468230020000041
Wherein R 1identical with above-mentioned definition.
Described formula 4 compounds are preferably 1:(1～5 with the mole dosage ratio of described sodiumazide) 1:(1.05～1.5 more preferably).
Described reaction solvent for use is preferably amides or ethers, or its any mixture.Described amide solvent is preferably DMF or N, N-diethyl acetamide.Described ether solvent is preferably tetrahydrofuran (THF), methyltetrahydrofuran.Solvent for use consumption is 1～50 times of formula 4 compounds, preferably 5～15 times.
The temperature of reaction of described reaction is 0～85 ℃, is preferably 40～65 ℃.Reaction times is 5～24 hours, is preferably 7～12 hours.
Five of the technical solution used in the present invention is: a kind of method for the preparation of formula 4 compounds is provided, has comprised the steps:
Following formula 3 compounds, under trifluoroacetic anhydride effect, generate described formula 4 compounds,
Wherein R 1identical with above-mentioned definition.
Described formula 4 compounds are preferably 1:(1～5 with the mole dosage ratio of described trifluoroacetic anhydride) 1:(1.0～1.5 more preferably).
Described reaction solvent for use is preferably halogenated hydrocarbon or aromatic halohydrocarbon class.Halogenated hydrocarbon is preferably methylene dichloride, chloroform, ethylene dichloride; Aromatic halohydrocarbon class is preferably benzene, toluene, ethylbenzene, chlorobenzene, bromobenzene.Solvent for use consumption is 5～50 times of formula 3 compounds, preferably 5～20 times.
The temperature of reaction of described reaction is preferably 0～45 ℃, more preferably 15～25 ℃.Reaction times is preferably 0～10 hour, more preferably 0.5～2 hour.
Wherein above-mentioned formula 3 compounds prepare by the following method:
(a) following formula 2 compounds, under the effect of alkali metal simple substance and initiator, generate the formula 2' compound of following formula
Figure BDA0000468230020000043
(b) above-mentioned formula 2' compound and reacting ethylene oxide, obtains above-mentioned formula 3 compounds.
In described step (a), described alkali metal simple substance is preferably magnesium, more preferably magnesium silk, magnesium rod, magnesium powder or magnesium chips.
In described step (a), the mole dosage of described formula 2 compounds and alkali metal simple substance is than being 1:(1～10) be preferably 1:(1～2)
In described step (a), described initiator is preferably iodine, idoalkane or brominated alkanes.The example of described idoalkane comprises methyl iodide, and the embodiment of described brominated alkanes comprises monobromethane, ethylene dibromide or its any two or more mixture.
In described step (a), described reaction solvent is preferably ethers, aromatic hydrocarbons, or its any two or more mixed solvent; Ether solvent is preferably ether, tetrahydrofuran (THF), 2-methyltetrahydrofuran.Aromatic hydrocarbon solvent is preferably benzene, toluene, or its any two or more mixed solvent.
In described step (a), described solvent load is 1～50 times of described formula 2 compounds, is preferably 5～30 times; Temperature of reaction is-10～35 ℃, preferably 0～25 ℃, and 0.5～18 hour reaction times, preferably 2～4 hours.
In described step (b), described formula 2' compound and the mole dosage of oxyethane are than being 1:(1～5) be preferably 1:(1.01～2); Temperature of reaction is-20～35 ℃, preferably 20～30 ℃.0.5～10 hour reaction times.
Wherein above-mentioned formula 2 compounds prepare by the following method:
Following formula 1 compound reacts with alkylating reagent and obtains above-mentioned formula 2 compounds under alkali and phase-transfer catalyst existence,
Figure BDA0000468230020000051
Wherein X is F, Cl, Br, I; R 1identical with above-mentioned definition.
X is preferably Br, I.
Described alkali is preferably mineral alkali, and described mineral alkali is specifically as follows sodium carbonate, salt of wormwood, saleratus, sodium bicarbonate, sodium hydroxide, potassium hydroxide, rubidium hydroxide or cesium hydroxide.
Described phase-transfer catalyst is preferably salt or microcosmic salt class, and described salt is preferably Tetrabutyl amonium bromide, 4-propyl bromide, tetraethylammonium bromide or 4 bromide.
Described alkylating reagent is preferably idoalkane, dialkyl carbonate hydrocarbon ester or sulfuric acid two alkane esters.
The mol ratio of described formula 1 compound and described mineral alkali is preferably 1:(1～10), more preferably 1:(3～6).
The mol ratio of described formula 1 compound and described phase-transfer catalyst is preferably 1:(0.01～0.1), be preferably 1:(0.02～0.06).
The mol ratio of described formula 1 compound and described methylating reagent is preferably 1:(1～10), more preferably 1:(3～6).
Described solvent is preferably benzene class, halogenated hydrocarbon or ethers, and described benzene class is preferably benzene, toluene; Described halogenated hydrocarbon is preferably methylene dichloride, chloroform, 1,1-ethylene dichloride; Described ethers is preferably tetrahydrofuran (THF), 2-methyltetrahydrofuran.
Described solvent load is 5～50 times of described formula 1 compound, is preferably 20～40 times; Temperature of reaction is-100～100 ℃, preferably 15～60 ℃, and 0.5～10 hour reaction times, preferably 2～4 hours.
Intermediate and the related manufacturing processes of what the present invention provided prepare Agomelatine, the acquisition of reaction raw materials 1-halogen-7-alkoxynaphtalene can be with reference to Helvetica Chimica Acta, 53 (6), 1294-1305; Easy the making of method in 1970.In brief, can under Sodium Nitrite and copper halide existence, react and obtain 1-halogen-7-naphthols with 1-amino-7-naphthols.The present invention has avoided using hypertoxic allyl methacrylate(AMA), and each step does not need column chromatography purification, can obtain highly purified product, and total recovery can reach 40%～50%.Therefore, the present invention, preparing aspect Agomelatine and derivative thereof, can effectively reduce production cost, and has that operation is simple and easy, reaction conditions relaxes, product yield high, has very high industrial application value.
Embodiment
Content for a better understanding of the present invention, is described further below in conjunction with specific embodiment, but concrete embodiment is not the restriction that content of the present invention is done.
The preparation of the bromo-7-methoxynaphthalene of embodiment 1:1-
In 250ml tetra-neck round-bottomed flasks, add successively the bromo-7-naphthols of 1-(5.6g, 0.025mol), 100ml toluene, methyl-sulfate (15.8g, 0.125mol) and 4 bromide (0.25g, 0.0015mol), start mechanical stirring.25～40 ℃ splash into 50%KOH aqueous solution 14.0g.Drip and finish, continue reaction.TLC monitors reaction, until the bromo-7-naphthols of raw material 1-transforms completely.Reaction is complete adds 10ml water, is warming up to 55～60 ℃, is incubated 1 hour.Layering, gets upper organic phase, abandons lower floor's water.Organic phase is successively with the sodium chloride aqueous solution washing of 5% aqueous sodium hydroxide solution and 5%.Solvent evaporated, obtains the bromo-7-methoxynaphthalene of the colourless wax-like solid matter 1-of 5.39g, yield 90.94%.
1H?NMR(400MHz,CDCl 3)3.94(s,3H),7.27-7.31(m,2H),7.43(s,1H),7.85(d,1H,J=7.2Hz),7.90-7.94(m,2H).
MS（EI +）：236[M +]
The preparation of the bromo-7-methoxynaphthalene of embodiment 2:1-
In 1000ml tetra-neck round-bottomed flasks, add successively the bromo-7-naphthols of 1-(22.3g, 0.10mol), 400ml toluene, methyl-sulfate (63.2g, 0.125mol) and Tetrabutyl amonium bromide (1.0g, 0.003mol) start mechanical stirring.10～15 ℃ splash into 50%KOH aqueous solution 56.0g.Drip and finish, continue reaction.TLC monitors reaction, until the bromo-7-naphthols of raw material 1-transforms completely.Reaction is complete adds 100ml water, is warming up to 55～60 ℃, is incubated 1 hour.Layering, gets upper organic phase, abandons lower floor's water.Organic phase is successively with the sodium chloride aqueous solution washing of 5% aqueous sodium hydroxide solution and 5%.Solvent evaporated, obtains the bromo-7-methoxynaphthalene of colourless waxy solid 1-22.52g, yield 95.0%.
The preparation of the bromo-7-propoxy-of embodiment 3:1-naphthalene
In 250ml tetra-neck round-bottomed flasks, add successively the bromo-7-naphthols of 1-(5.6g, 0.025mol), 100ml toluene, propyl sulfate (22.8g, 0.125mol) and 4-propyl bromide (0.4g, 0.0015mol), start mechanical stirring.25～40 ℃ splash into 50%KOH aqueous solution 14.0g.Drip and finish, continue reaction.TLC monitors reaction, until the bromo-7-naphthols of raw material 1-transforms completely.Reaction is complete adds 10ml water, is warming up to 55～60 ℃, is incubated 1 hour.Layering, gets upper organic phase, abandons lower floor's water.Organic phase is successively with the sodium chloride aqueous solution washing of 5% aqueous sodium hydroxide solution and 5%.Solvent evaporated, obtains the bromo-7-propoxy-of the colourless wax-like solid matter 1-of 6.08g naphthalene, yield 91.83%.
MS（EI +）：264[M +]
The preparation of the bromo-7-isopentyloxy of embodiment 4:1-naphthalene
Method according to embodiment 1 operates with method, gets the bromo-7-naphthols of 1-(5.6g, 0.025mol) reaction, makes the bromo-7-isopentyloxy of the colourless wax-like solid matter 1-of 6.34g naphthalene, yield 86.56%.
MS（EI +）：292[M +]
The preparation of the chloro-7-methoxynaphthalene of embodiment 5:1-
Method according to embodiment 1 operates with method, gets the chloro-7-naphthols of 1-(4.45g, 0.025mol) reaction, makes the chloro-7-methoxynaphthalene of the colourless wax-like solid matter 1-of 4.31g, yield 89.28%.
MS（EI +）：192[M +]
The preparation of embodiment 6:7-methoxyl group-1-naphthyl ethyl alcohol
In 500ml tetra-neck round-bottomed flasks, add magnesium silk (5.5g, 0.229mol), after the air in nitrogen replacement flask, add 100ml tetrahydrofuran (THF), 1 iodine and 0.3ml1,2-ethylene dibromide, 20～25 ℃ of stirrings.After the color fade of iodine, drip tetrahydrofuran (THF) (200ml) solution of the bromo-7-methoxynaphthalene of 1-(40.17g, 0.169mol).When system temperature obviously rises, stop dripping, be cooled to below 30 ℃.Afterwards, drip the tetrahydrofuran solution of the bromo-7-methoxynaphthalene of all the other 1-in 25～30 ℃ of continuation.Drip and finish, 20～25 ℃ are incubated 2 hours.
In another 1000ml tetra-neck round-bottomed flasks, add 250ml anhydrous tetrahydro furan, nitrogen protection borehole cooling to 0 ℃, adds oxyethane (9.06g, 0.21mol).0～5 ℃ drips the above-mentioned grignard reagent preparing, within approximately 3 hours, drips off.Dropwise, 0～5 ℃ is incubated 16 hours.Reaction is finished, and the dilute hydrochloric acid of 105g8% is added in reaction feed liquid, and underpressure distillation, reclaims tetrahydrofuran (THF).Distillation completes, with the ethyl acetate extraction of 250ml × 2, the washing of 200ml5% sodium chloride aqueous solution, 5.0g anhydrous sodium sulfate drying.Solvent evaporated, adds 200ml normal heptane and 50ml ethyl acetate in residue, pulls an oar 3 hours for 20～25 ℃, and suction filtration.Filter cake is in 40 ℃ of decompression dryings, final 25.1g solid 7-methoxyl group-1-naphthyl ethyl alcohol, yield 73.61%.
1H?NMR(400MHz,CDCl3)3.27-3.30(t,J=6.4Hz,2H),3.92(s,3H),3.98(t,J=6.0Hz,2H),7.14-7.17(m,1H),7.24-7.33(m,3H),7.67(d,1H,J=8.0Hz),7.75(d,1H,J=8.8Hz).
MS（EI+）：202[M+]，184[M-H2O]+.
The preparation of embodiment 7:7-oxyethyl group-1-naphthyl ethyl alcohol
Method according to embodiment 6 operates with method, gets 1-bromo-7-oxyethyl group naphthalene (4.5g, 0.017mol) reaction, makes 2.47g7-oxyethyl group-1-naphthyl ethyl alcohol, yield 67.13%.
The preparation of embodiment 8:7-propoxy--1-naphthyl ethyl alcohol
Method according to embodiment 6 operates with method, gets 1-bromo-7-propoxy-naphthalene (4.5g, 0.015mol) reaction, makes 2.11g7-propoxy--1-naphthyl ethyl alcohol, yield 61.24%.
The preparation of embodiment 9:7-isopentyloxy-1-naphthyl ethyl alcohol
Method according to embodiment 6 operates with method, gets the chloro-7-methoxynaphthalene of 1-(4.5g, 0.023mol) reaction, makes 3.18g7-methoxyl group-1-naphthyl ethyl alcohol, yield 53.61%.
Embodiment 10:2,2,2-trifluoroacetic acid-2-(7-methoxy-1-naphthyl) preparation of ethyl ester
In three neck round-bottomed flasks, add 7-methoxyl group-1-naphthyl ethyl alcohol (5.0g, 0.025mmol) and 100ml methylene dichloride, start magnetic agitation.Be cooled to 0 ℃～5 ℃, at this temperature, drip trifluoroacetic anhydride (10.4g, 0.049mmol).Drip and finish, be warming up to 20 ℃～25 ℃, continue reaction 10 hours.TLC monitors reaction, until raw material 7-methoxyl group-1-naphthyl ethyl alcohol transforms completely.Reaction is finished, successively by 30ml8% sodium bicarbonate aqueous solution and 30ml5% sodium chloride aqueous solution washing feed liquid.Solvent evaporated, obtains 7.0g water white transparency oily 2,2,2-trifluoroacetic acid-2-(-7-methoxy-1-naphthyl) ethyl ester, yield 95.01%.
1H?NMR(400MHz,CDCl3)3.37(t,2H,J=7.6Hz),3.91(s,3H),3.27(t,2H,J=7.6Hz),7.13-7.16(m,1H),7.21-7.27(m,2H),7.30(d,1H,J=2.4Hz),7.65-7.67(m,1H),7.71(d,1H,J=9.2Hz)。
19F?NMR(375MHz,CDCl3)-74.0。
MS（EI+）：298[M+]。
Embodiment 11:2,2,2-trifluoroacetic acid-2-(7-oxyethyl group-1-naphthyl) preparation of ethyl ester
Method according to embodiment 10 operates with method, gets 7-oxyethyl group-1-naphthyl ethyl alcohol (5g, 0.023mol) reaction, makes 6.48g water white transparency oily 2,2,2-trifluoroacetic acid-2-(7-oxyethyl group-1-naphthyl) ethyl ester, yield: 90.31%.
MS（EI+）：312[M+]。
Embodiment 12:2,2,2-trifluoroacetic acid-2-(7-propoxy--1-naphthyl) preparation of ethyl ester
Method according to embodiment 10 operates with method, gets 7-propoxy--1-naphthyl ethyl alcohol (5g, 0.022mol) reaction, makes 6.11g water white transparency oily 2,2,2-trifluoroacetic acid-2-(7-propoxy--1-naphthyl) ethyl ester, yield: 85.27%.
MS（EI+）：326[M+]。
Embodiment 13:2,2,2-trifluoroacetic acid-2-(7-isopentyloxy-1-naphthyl) ethyl ester
Method according to embodiment 10 operates with method, gets 7-isopentyloxy-1-naphthyl ethyl alcohol (5g, 0.019mol) reaction, makes 4.91g water white transparency oily 2,2,2-trifluoroacetic acid-2-(7-isopentyloxy-1-naphthyl) ethyl ester, yield: 72.94%.
MS（EI+）：354[M+]。
Embodiment 14:1-(2-azidoethyl) preparation of-7-methoxynaphthalene
In the mono-neck round-bottomed flask of 250ml, add 2,2,2-trifluoroacetic acid-2-(7-methoxy-1-naphthyl) ethyl ester (5.0g, 0.017mol) and 150mlN, dinethylformamide, is warming up to 30 ℃～35 ℃, splash into sodiumazide (4.45g, 0.068mol) aqueous solution 10ml.Drip and finish, be warming up to 55 ℃～60 ℃, insulation reaction 8 hours.Reaction is finished, and reaction feed liquid is poured in 200ml water, and the ethyl acetate extraction of 150ml × 2, merges organic phase.After the sodium chloride aqueous solution washing of organic phase with 150ml5%, solvent evaporated, obtains 3.86g water white transparency oily 1-(2-azidoethyl)-7-methoxynaphthalene, productive rate 100%.
1H?NMR(400MHz,CDCl3)3.45(t,2H,J=7.6Hz),3.66(t,2H,J=7.6Hz),3.98(s,3H),7.20-7.23(m,1H),7.27-7.38(m,2H),7.73(d,1H,J=8.0Hz),7.81(d,1H,J=8.8Hz).
MS（EI+）：227[M+]。
Embodiment 15:1-(2-azidoethyl) preparation of-7-oxyethyl group naphthalene
Method according to embodiment 14 operates with method, gets 2,2,2-trifluoroacetic acid-2-(7-oxyethyl group-1-naphthyl) ethyl ester (5g, 0.016mol) reaction, make 3.85g water white transparency oily 1-(2-azidoethyl) and-7-oxyethyl group naphthalene, yield: 100%.
MS（EI+）：241[M+]。
Embodiment 16:1-(2-azidoethyl) preparation of-7-propoxy-naphthalene
Method according to embodiment 14 operates with method, gets 2,2,2-trifluoroacetic acid-2-(7-propoxy--1-naphthyl) ethyl ester (5g, 0.015mol) reaction, make 3.91g water white transparency oily 1-(2-azidoethyl) and-7-propoxy-naphthalene, yield: 100%.
MS（EI+）：255[M+]。
Embodiment 17:1-(2-azidoethyl) preparation of-7-isopentyloxy naphthalene
Method according to embodiment 14 operates with method, gets 2,2,2-trifluoroacetic acid-2-(7-isopentyloxy-1-naphthyl) ethyl ester (5g, 0.014mol) reaction, make 4.0g water white transparency oily 1-(2-azidoethyl) and-7-isopentyloxy naphthalene, yield: 100%.
MS（EI+）：283[M+]。
Embodiment 18:2-(7-methoxyl group naphthyl) preparation of ethamine
In 100ml stainless steel autoclave, add 1-(2-azidoethyl)-7-methoxynaphthalene (5.0g, 22mmol)), 0.5g5%Pd-C catalyzer and 50ml methyl alcohol, after the air in hydrogen exchange flask, sealing equipment.15 ℃～20 ℃ pressurization hydrogenation, hydrogen pressure P=1～1.5Mpa.React 8 hours.Reaction is finished, and filters, and reclaims Pd-C catalyzer.Filtrate decompression evaporate to dryness, obtains 4.42g water white transparency oily 2-(7-methoxyl group naphthyl) ethamine, yield 99.77%.
1H?NMR(400MHz,CDCl3)3.08-3.18(m,4H),3.91(s,3H),7.14-7.16(m,1H),7.24-7.30(m,3H),7.65(d,1H,J=4.0Hz),7.73-7.76(m,1H).
MS（EI+）：201[M+]。
Embodiment 19:2-(7-oxyethyl group naphthyl) preparation of ethamine
Method according to embodiment 17 operates with method, gets 1-(2-azidoethyl)-7-oxyethyl group naphthalene (3g, 0.012mol), make 2.55g water white transparency oily 2-(7-oxyethyl group naphthyl) and ethamine, yield: 98.89%.
MS（EI+）：215[M+]。
Embodiment 20:2-(7-propoxy-naphthyl) preparation of ethamine
Method according to embodiment 17 operates with method, gets 1-(2-azidoethyl)-7-propoxy-naphthalene (3g, 0.012mol), make 2.62g water white transparency oily 2-(7-propoxy-naphthyl) and ethamine, yield: 97.11%.
MS（EI+）：229[M+]。
Embodiment 21:2-(7-isopentyloxy naphthyl) preparation of ethamine
Method according to embodiment 17 operates with method, gets 1-(2-azidoethyl)-7-isopentyloxy naphthalene (3g, 0.011mol), make 2.52g water white transparency oily 2-(7-isopentyloxy naphthyl) and ethamine, yield: 92.33%.
MS（EI+）：257[M+]。
Embodiment 22:N-[2-(7-methoxy-1-naphthyl) ethyl] preparation of ethanamide
In 500ml tri-neck round-bottomed flasks, add 2-(7-methoxyl group naphthyl) ethamine (10.0g, 0.05mol), add 2500ml methylene dichloride and triethylamine (7.5g, 0.0745mol), start and stir.Nitrogen protection borehole cooling to 0 ℃～5 ℃.Drip Acetyl Chloride 98Min. (5.9g, 0.00745mol) in 0 ℃～5 ℃.Drip and finish, be warming up to 20 ℃～25 ℃, continue reaction 10 hours until raw material transforms completely.Reaction is finished, solvent evaporated.In residue, add 50% aqueous ethanolic solution 100ml recrystallization, filter, dry, obtain 11.3g white solid N-[2-(7-methoxy-1-naphthyl) ethyl] ethanamide, yield 92.89%, HPLC >=99.9%.
1H?NMR(400MHz,CDCl3)1.93(s,3H),3.23(t,2H,J=7.6Hz),3.56-3.61(m,2H),3.98(s,3H),5.86(bs,1H),7.15-7.18(m,1H),7.24-7.27(m,2H),7.48(d,1H,J=1.6Hz),7.66-7.68(m,1H),7.74(d,1H,J=9.2Hz).
MS（EI+）：243[M+]。
Embodiment 23:N-[2-(7-oxyethyl group-1-naphthyl) ethyl] preparation of ethanamide
Method according to embodiment 22 operates with method, gets 2-(7-oxyethyl group naphthyl) ethamine (2g, 0.009mol), make 2.08g white solid N-[2-(7-oxyethyl group-1-naphthyl) ethyl] and ethanamide, yield: 90.13%
MS（EI+）：257[M+]。
Embodiment 24:N-[2-(7-propoxy--1-naphthyl) ethyl] preparation of ethanamide
Method according to embodiment 22 operates with method, gets 2-(7-propoxy-naphthyl) ethamine (2g, 0.009mol), make 2.03g white solid N-[2-(7-propoxy--1-naphthyl) ethyl] and ethanamide, yield: 86.01%
MS（EI+）：271[M+]。
Embodiment 25:N-[2-(7-isopentyloxy-1-naphthyl) ethyl] preparation of ethanamide
Method according to embodiment 22 operates with method, gets 2-(7-isopentyloxy naphthyl) ethamine (2g, 0.008mol), make 1.69g white solid N-[2-(7-isopentyloxy-1-naphthyl) ethyl] and ethanamide, yield: 72.62%
MS（EI+）：299[M+]。
In sum, the present invention relates to intermediate and the related manufacturing processes of Agomelatine, above-mentioned preparation method obtains formula 2 compounds take 1-halogen-7-alkoxynaphtalene as raw material through alkylated reaction, formula 2 compounds that obtain carry out grignard reaction and obtain formula 3 compounds, formula 3 compounds that obtain react the formula of obtaining 4 compounds with trifluoroacetic anhydride, formula 4 compounds are the new midbody compound of synthetic Agomelatine and derivative thereof.Can obtain formula 5 compounds with up-to-date style 4 compounds and reaction of sodium azide, formula 5 compounds are also the new midbody compounds of synthetic Agomelatine and derivative thereof.Formula 5 compounds, through the reaction of the simple types such as hydro-reduction, electrophilic substitution, can obtain being applicable to Agomelatine and the derivative thereof of suitability for industrialized production.
It should be noted that all documents of mentioning in the present invention quote as a reference in this application, just quoted separately as a reference as each piece of document.In addition should understand, above-described is specific embodiments of the invention and the know-why used, after having read foregoing of the present invention, those skilled in the art can make various changes or modifications and not deviate from spirit of the present invention and scope the present invention, and these equivalent form of values fall within the scope of the invention equally.

Claims (7)

1. the compound having as shown in the formula (4) structure:
Figure FDA0000468230010000011
Wherein: R 1for alkyl.
2. the purposes of compound according to claim 1, is characterized in that, can be used for preparing Agomelatine.
3. the preparation method of formula according to claim 1 (4) compound, is characterized in that, prepared under trifluoroacetic anhydride effect by following formula (3) compound,
Wherein R 1definition identical with the definition of claim 1.
4. preparation method according to claim 3, it is characterized in that, comprise further step: by formula (2) compound under the effect of alkali metal simple substance and initiator, generate formula (the 2 ') compound of following formula, formula (the 2 ') compound obtaining and reacting ethylene oxide prepare described formula (3) compound
Figure FDA0000468230010000013
Wherein R 1definition identical with the definition of claim 1.
5. preparation method according to claim 4, is characterized in that, comprises further step: formula (1) compound is reacted with alkylating reagent and prepares described formula (2) compound under alkali and phase-transfer catalyst existence,
Wherein X is F, Cl, Br or I; R 1definition identical with the definition of claim 1.
6. preparation method according to claim 5, is characterized in that, wherein said phase-transfer catalyst is salt or microcosmic salt class.
7. preparation method according to claim 5, is characterized in that, wherein said alkylating reagent is idoalkane, dialkyl carbonate hydrocarbon ester or sulfuric acid two alkane esters.
CN201410060403.5A 2010-12-21 2010-12-21 Midbody for preparing agomelatine and preparation method thereof Active CN103833553B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410060403.5A CN103833553B (en) 2010-12-21 2010-12-21 Midbody for preparing agomelatine and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410060403.5A CN103833553B (en) 2010-12-21 2010-12-21 Midbody for preparing agomelatine and preparation method thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201010615618.0A Division CN102531956B (en) 2010-12-21 2010-12-21 Intermediate for preparing agomelatine and relevant preparation method

Publications (2)

Publication Number Publication Date
CN103833553A true CN103833553A (en) 2014-06-04
CN103833553B CN103833553B (en) 2015-06-10

Family

ID=50797494

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410060403.5A Active CN103833553B (en) 2010-12-21 2010-12-21 Midbody for preparing agomelatine and preparation method thereof

Country Status (1)

Country Link
CN (1) CN103833553B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107353229A (en) * 2017-08-08 2017-11-17 许昌恒生制药有限公司 A kind of preparation method of agomelatine intermediate body

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101234955A (en) * 2008-03-10 2008-08-06 孔繁昇 Method for preparing 3-methoxyl-4-t-butyltoluene
CN101638376A (en) * 2008-07-29 2010-02-03 江苏恩华药业股份有限公司 Method for preparing agomelatine and intermediate of agomelatine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101234955A (en) * 2008-03-10 2008-08-06 孔繁昇 Method for preparing 3-methoxyl-4-t-butyltoluene
CN101638376A (en) * 2008-07-29 2010-02-03 江苏恩华药业股份有限公司 Method for preparing agomelatine and intermediate of agomelatine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MICHAEL D. BENTLEY ET AL.: "The Solvolysis of 2-Arylethyl p-Toluenesulfonates", 《JOURNAL OF THE AMERICAN CHEMICAL SOCIETY》 *
W.E.BACHMANN ET AL.: "The Synthesis of 2-hydroxy-17-equilenone", 《JOURNAL OF THE AMERICAN CHEMICAL SOCIETY 》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107353229A (en) * 2017-08-08 2017-11-17 许昌恒生制药有限公司 A kind of preparation method of agomelatine intermediate body

Also Published As

Publication number Publication date
CN103833553B (en) 2015-06-10

Similar Documents

Publication Publication Date Title
CN110950765A (en) Preparation method of terbutaline sulfate
CN102712572B (en) Process for obtaining 3,3-diphenylpropylamines
CN102531956B (en) Intermediate for preparing agomelatine and relevant preparation method
CN101654419A (en) Preparation method of fluvoxamine maleate
CN106565510A (en) Preparation method for trans 4-amino-cyclohexyl acetate derivative
CN103833553B (en) Midbody for preparing agomelatine and preparation method thereof
CN103896795B (en) The preparation method and its usage of benzamide compound, its intermediate
KR20130028134A (en) Agomelatine intermediates and preparation method thereof
EP2921473A1 (en) 1-cyan-1-(7-methoxyl-1-naphtyl) methanol ester compound and preparation method and use thereof
CN106748966A (en) A kind of synthetic method of Ramipril key intermediate
CN102942501B (en) The production method of Agomelatine is prepared in a kind of hydrogenation
CN104803861B (en) Method for synthesizing tapentadol hydrochloride
CN110483274A (en) A kind of preparation method of cyclopentolate hydrochloride intermediate
CN101973897B (en) Synthesis method of valdoxan intermediate 2-(7-methoxy-1-naphthyl)ethylamine
CN105001105A (en) Preparation method of 2-methylamino-5-chlorobenzophenone
CN102875415B (en) Compound and preparation method and application thereof
CN103288650A (en) Hydrochloric acid 1-amino-3, 5-dimethyl adamantane preparation method
CN111100042B (en) Preparation method of 2-methoxy-5-sulfonamide benzoic acid
CN108084077B (en) Synthetic method of zafirlukast intermediate
CN103183680A (en) Method for preparing asenapine
CN101265201B (en) Method for synthesizing tramadol hydrochloride
CN102993040B (en) A kind of novel method of synthesizing Agomelatine
CN1300079C (en) New technology of synthesizing 4-[2-(cyclo propyl methoxy] ethyl] phenol
CN110818677A (en) Process for the preparation of cyclohexane derivatives
CN107573212A (en) The synthetic method of trans 4 alkyl-cyclohexyl benzene structure liquid crystal intermediates and monomer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant